Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Controlled Methylphenidate for Cancer Related Fatigue
NCT02361125Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2002
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methylphenidate hydrochloride extended-release chewable tablet in cancer-related fatigue (CRF), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Fatigue Measurement on a 10-point scale at 7 days. Started Aug 2002; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT02361125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361125.